JC06 Rec'd PCT/PTO 12 SEP 2005 PCT

Date: September 2005 I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Kim Blum	Kem Dun
Name (Print)	Signature

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	DOI et al.	)	Examiner:	Unassigned
Application No.:	10/526,234	)	Group Art Unit:	Unassigned
Filed:	February 28, 2005	)	Confirmation No.:	7447
Docket No.:	3190-072	)	Customer No.:	33432

For: Method of Degradation, Method for Inhibiting Degradation, and Agent for Inhibiting Degradation, for Transcription Factors of Glucose Metabolism-Related Genes (as amended)

# RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

September 9, 2005

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated September 2, 2005, the applicants respond as follows.

In the Notification, it was asserted that the content of the computer readable form does not comply with the requirements of 37 C.F.R. §1.822 and/or § 1.823.

To fully respond to this Notification, enclosed is a second diskette containing a computer readable form of the "Sequence Listing." This is a substitute computer readable from (CRF) copy of the "Sequence Listing." Also enclosed is a Statement under 37 C.F.R. § 1.821, along with a

Response to Notification to Comply With Requirements

for Patent Applications Containing Nucleotide

and/or Amino Acid Sequence Disclosures

U.S. Patent Application No. 10/526,234

printed version of the "Sequence Listing." The printed version of the "Sequence Listing" has been

updated to reflect the current assigned U.S. patent application number for the present application

and to remove the page numbering. Accordingly, the applicants have fully responded to the

notification.

**CONCLUSION** 

In view of the foregoing remarks, the applicant respectfully requests the reconsideration of

this application and the timely allowance of the pending claims.

If there are any fees due in connection with the filing of this response, please charge the fees

to Deposit Account No. 50-0925. If a fee is required for an extension of time under 37 C.F.R. §

1.136 not accounted for above, such extension is requested and should also be charged to said

Deposit Account.

Respectfully submitted,

Luke A. Kilyk

B.C. H

Reg. No. 33,251

Atty. Docket No. 3190-072

KILYK & BOWERSOX, P.L.L.C.

53 A East Lee Street

Warrenton, VA 20186

Tel.:

(540) 428-1701

Fax:

(540) 428-1720

Enclosures:

Statement Under 37 C.F.R. § 1.821

Printed version of the "Sequence Listing"

Diskette containing a computer readable form of the "Sequence Listing."

Copy of Notice to Comply with Requirements

-2-



#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

10/526,234

Hirofumi Doi

3190-072

Kilyk & Bowersox 53 A East Lee Street

Warrenton, VA 20186

KILYK & BOWERSOX, P.L.L.C.

INTERNATIONAL APPLICATION NO. PCT/JP03/11046 I.A. FILING DATE PRIORITY DATE 08/29/2003 08/30/2002

**CONFIRMATION NO. 7447 371 FORMALITIES LETTER** 

Date Mailed: 09/02/2005

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

**Docketed** 

Due Date \_\_1/2-/ 53 Dkt No \_3190-072

and S.W. or contains taxes

Telephone: (703) 308-9140 EXT 227

## PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/526,234	PCT/JP03/11046	3190-072

FORM PCT/DO/EO/922 (371 Formalities Notice)